A5102918516- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- HIV/AIDS drug development and treatment
- Systemic Lupus Erythematosus Research
- Liver Disease and Transplantation
- Ionic liquids properties and applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Liver Diseases and Immunity
- Immune Cell Function and Interaction
- Alcohol Consumption and Health Effects
- Renal Transplantation Outcomes and Treatments
- Electrochemical Analysis and Applications
- Chronic Lymphocytic Leukemia Research
- Diet and metabolism studies
- Alzheimer's disease research and treatments
- Cerebrovascular and Carotid Artery Diseases
- Pneumocystis jirovecii pneumonia detection and treatment
- Blood groups and transfusion
- Monoclonal and Polyclonal Antibodies Research
- Glioma Diagnosis and Treatment
- Vitamin D Research Studies
- Diabetes and associated disorders
Shinmatsudo Central General Hospital
2017-2024
Fukuoka University
2024
Hudson Institute
2020
Katsushika Medical Center
2003-2018
Jikei University School of Medicine
2006-2018
National Defence Academy
2014
National Defense Academy of Japan
2005-2013
The Jikei University Hospital
2003-2011
RIKEN Center for Integrative Medical Sciences
2010
Hiroshima University
2010
There are limited data on antiviral treatment
<h3>Background and aims</h3> A number of recent studies have shown that human polymorphisms near the <i>IL28B</i> type III interferon (IFNλ) gene influence response to peg-interferon plus ribavirin combination therapy for infection with chronic hepatitis C virus (HCV). Viral polymorphisms, including substitutions within HCV core NS5A proteins, also been treatment outcome, but it is not known whether these factors act independently IL28B polymorphism or if they reflect same a different...
To evaluate the efficacy and safety of oral semaglutide for type 2 diabetes mellitus (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Patients with chronic hepatitis C are often complicated by kidney disease (CKD).To evaluate the efficacy, safety and pharmacokinetics of glecaprevir/pibrentasvir in patients severe renal impairment.In a prospective, multicentre study involving 35 medical institutions, 832 genotype 1-3 were treated glecaprevir/pibrentasvir. The efficacy analysed for CKD stage 4 or 5. Multivariate analysis was performed to identify factors associated most frequently observed adverse event. In undergoing...
Summary Background Racial and ethnic disparities exist for hepatitis C virus (HCV) treatment hepatocellular carcinoma (HCC) survival. Aim To evaluate the impact of HCV on such disparities. Methods In a retrospective cohort study, we analysed 6069 patients with HCV‐related HCC (54.2% Asian, 30.1% White, 8.5% Black, 7.3% Hispanic) from centres in United States Asia. Results The mean age was 61, 60, 59 68, respectively, Hispanic Asian patients. Black were most likely to have Barcelona Clinic...
From a pharmacokinetic viewpoint, the use of ombitasvir/paritaprevir/ritonavir, one standards care for genotype 1b chronic hepatitis C in Japan, could be possible patients with impaired renal function. The aim this study was to assess efficacy and safety combination that have not yet been addressed undergoing dialysis.A retrospective, multicenter evaluated outcome 12-week ombitasvir (non-structural protein [NS]5A inhibitor)/paritaprevir (NS3/4A protease inhibitor)/ritonavir therapy dialysis...
Abstract Nonalcoholic fatty liver disease (NAFLD) is related to subclinical atherosclerosis. However, whether the severity of (or which histopathological component) associated with atherosclerosis remains controversial. This study aimed investigate association between NAFLD and carotid intima-media thickness (CIMT) in Japanese patients biopsy-proven NAFLD. Maximum-CIMT (max-CIMT) was measured as an index 195 patients. A significant observed fibrosis (but not steatosis, inflammation,...
This study explored treatment outcomes of sofosbuvir (SOF)/ledipasvir (LDV) therapy for chronic hepatitis C patients with and without prior daclatasvir (DCV)/asunaprevir (ASV) therapy.Overall, 530 Japanese who were infected virus genotype 1 received SOF/LDV 12 weeks, resistance-associated variants (RAVs) in the non-structural protein (NS)5A NS5B regions assessed at baseline virological relapse by direct sequencing.Sustained response (SVR) rates did not significantly differ between NS5A...
Standard-dose ribavirin is crucial for the standard-of-care treatment of chronic hepatitis C virus (HCV) infection. Equilibrative nucleoside transporter 1 (ENT1), encoded by SLC29A1 gene, main that imports into human hepatocytes.To determine whether single nucleotide polymorphisms (SNPs) at gene could influence probability response compared with other baseline and host genetic factors.A total 526 East Asian patients monoinfected HCV genotype 1b who had received pegylated interferon alpha...
Abstract Background and Aim This study aimed to evaluate the efficacy safety of elbasvir/grazoprevir in genotype 1b chronic hepatitis C Japanese patients with kidney disease (CKD), including those undergoing hemodialysis. Methods post hoc analysis a multicenter, retrospective included who had received elbasvir/grazoprevir. CKD was defined by an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 . The sustained virologic response (SVR) frequency treatment‐emergent adverse...
Abstract Background In clinical trials, a pangenotype direct‐acting antiviral (DAA) regimen consisting of glecaprevir (GLE) and pibrentasvir (PIB) exhibited high virologic efficacy tolerability in patients with hepatitis C virus (HCV) infection. This study sought to confirm these findings real‐world settings, focusing on cirrhosis, history DAA failure, or HCV genotype 3 who were treated 12‐week large multicenter from Japan. Methods nationwide prospective cohort study, we analyzed background...
The role of HLA-DR antigens in the clinicopathological features autoimmune hepatitis (AIH) is not clearly understood. We examined implications Japanese AIH, including effect HLA-DR4 on age and pattern AIH onset, features, treatment efficacy. A total 132 patients consecutively diagnosed treated 2000–2014 at 2 major hepatology centers eastern Tokyo district were subjects this study. frequency phenotypes was compared with that healthy population. divided into HLA-DR4–positive or...
We aimed to clarify the influences of aldehyde dehydrogenase 2 (ALDH2), alcohol 1B (ADH1B) polymorphisms, and ethanol consumption profile hepatocellular carcinoma (HCC) development in alcoholic liver cirrhosis without chronic hepatitis B C virus infection (non-B non-C).Of 236 freshly diagnosed non-B non-C patients, 67 were as HCC remaining 169 not having HCC. The relationship between genetic polymorphisms evaluated well-matched patients with (HCC group, n = 67) (non-HCC using propensity...
The aim of this study was to clarify the effects and safety ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) therapy in genotype 1b chronic hepatitis C patients with non-dialysis kidney disease (CKD).This retrospective, multicenter 12-week OBT/PTV/r included CKD. Chronic defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 . Virologic responses treatment-emergent adverse events (TEAEs) CKD were compared those without CKD.Two hundred thirty-five a median age 67 years...
We investigated changes in patient characteristics, rate of sustained virologic response (SVR), and factors associated with SVR after anti-hepatitis C virus (HCV) therapy direct-acting antiviral (DAA) regimens real-world practice Japan, where patients HCV are characterized by older age high prevalence cirrhosis hepatocellular carcinoma (HCC).Changes characteristics rates were evaluated from medical records among 10 688 who started interferon (IFN)-free DAA between September 2014 June 2018 a...